Indication
Triple Negative Breast Cancer
30 clinical trials
51 products
13 drugs
Product
EnzalutamideClinical trial
A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTAMIDE IN PATIENTS WITH ADVANCED, ANDROGEN RECEPTOR-POSITIVE, TRIPLE-NEGATIVE BREAST CANCERStatus: Completed, Estimated PCD: 2015-03-01
Clinical trial
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast CancerStatus: Terminated, Estimated PCD: 2023-02-06
Product
LAG525Product
canakinumabProduct
spartalizumabProduct
NIR178Product
capmatinibProduct
MCS110Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid TumoursStatus: Recruiting, Estimated PCD: 2024-06-01
Product
[225Ac]-FPI-1434Clinical trial
A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesStatus: Completed, Estimated PCD: 2020-05-26
Product
Talimogene LaherparepvecProduct
AtezolizumabProduct
FPI-1175Product
FPI-1547Product
OlaparibClinical trial
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).Status: Active (not recruiting), Estimated PCD: 2020-11-13
Product
CeralasertibProduct
Adavosertib + OlaparibProduct
[225Ac]-FPI-1434 InjectionProduct
mRNA-2752Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint BlockadeStatus: Active (not recruiting), Estimated PCD: 2024-05-15
Product
DurvalumabProduct
Ceralasertib + OlaparibProduct
TenalisibClinical trial
A Phase II, Multi-center, Single-arm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K δ/γ, and SIK3 Inhibitor, in Patients With Metastatic Triple Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid TumorsStatus: Terminated, Estimated PCD: 2021-10-29
Product
GEN1044Product
PembrolizumabProduct
Nab-paclitaxelProduct
PaclitaxelProduct
GemcitabineProduct
CarboplatinProduct
Normale SalineClinical trial
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)Status: Completed, Estimated PCD: 2021-06-15
Clinical trial
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.Status: Terminated, Estimated PCD: 2022-10-17
Clinical trial
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2020-07-14
Product
CyclophosphamideProduct
N-803Clinical trial
Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior TherapyStatus: Terminated, Estimated PCD: 2023-01-04
Product
Sacituzumab GovitecanProduct
PD-L1 t-haNKProduct
TRX518Product
AvelumabClinical trial
A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-03-01
Product
B013+Nab-PaclitaxelClinical trial
A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2026-01-01
Product
FludarabineDrug
cyclophosphamideProduct
PRGN-3007Clinical trial
A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation TherapyStatus: Completed, Estimated PCD: 2022-12-19
Product
cisplatinClinical trial
Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2022-02-20
Drug
AN0025Drug
AbraxaneClinical trial
A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2023-01-30
Clinical trial
A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-09-01
Drug
AtezolizumabDrug
GemcitabineClinical trial
Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer PatientsStatus: Completed, Estimated PCD: 2021-01-01
Product
L-NMMAClinical trial
A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)Status: Not yet recruiting, Estimated PCD: 2027-07-01
Drug
PM8002Drug
Nab-PaclitaxelProduct
PlaceboClinical trial
An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-22
Product
Veliparib + LapatinibClinical trial
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2027-09-30
Product
Liposomal DoxorubicinClinical trial
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor TypesStatus: Recruiting, Estimated PCD: 2024-08-31
Product
NX-1607Drug
TiragolumabClinical trial
Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)Status: Recruiting, Estimated PCD: 2024-11-01
Product
TalazoparibDrug
SelinexorClinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2025-08-01
Product
AB598Product
ZimberelimabProduct
PemetrexedDrug
fluorouracilDrug
mFOLFOX6Clinical trial
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase 1 Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Ligand in Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-20
Product
PLD ChemotherapyDrug
CDX-1140Drug
CDX-301Clinical trial
A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative CancersStatus: Recruiting, Estimated PCD: 2025-10-01
Product
LeflunomideClinical trial
Clinical Study on the Safety and Efficacy of GK01 Autologous Tumor-reactive T Cells (TRT) in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-07-19
Product
TCR T-cellsClinical trial
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating LymphocytesStatus: Not yet recruiting, Estimated PCD: 2032-09-15
Product
Adjuvant chemotherapy